12:00 AM
 | 
Oct 05, 2009
 |  BC Week In Review  |  Company News  |  Deals

Eisai, Pfizer deal

The partners settled a dispute over Alzheimer's disease (AD) drug Aricept donepezil. Pfizer will return its Japanese rights to Eisai in December 2012 but retains rights to the reversible acetylcholinesterase (AChE) inhibitor in its other...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >